ORIC-259
/ ORIC Pharma, Cancer Research UK
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 05, 2026
ORIC Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
(GlobeNewswire)
- "Under the agreement, Cancer Research UK’s Centre for Drug Development (CDD) will fully fund, sponsor, design, and execute CTA-enabling studies and early clinical development of ORIC-259 for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with Cancer Research UK eligible to receive downstream milestone payments and royalties."
Licensing / partnership • Oncology
1 to 1
Of
1
Go to page
1